

## Evariste Boosts Research Operations with Adoption of CDD Vault

OXFORD, UNITED KINGDOM, May 31, 2023 /EINPresswire.com/ -- Evariste, a leading Al-driven drug discovery company with an end-to-end platform for finding and optimizing novel candidate drugs, announced today that it has enhanced its operations by adopting CDD Vault, a cloud-based platform for managing research data and collaborations designed and developed by Collaborative Drug Discovery, Inc.

Evariste is a research and development company with a mission to accelerate the delivery of new therapies through Al-based innovative solutions. The company has a highly scalable Hit-to-Candidate platform that enables the designing and scoring of synthetically accessible drug candidates. Evariste has a set of advanced internal projects around synthetic lethality, immuno-oncology and DNA damage response. In addition, Evariste collaborates with other research organisations using the platform to advance their drug discovery programs.

"Adopting CDD Vault is a great step forward for Evariste," said Anna Hercot,





CEO of the company. "Our research operations will now be streamlined, allowing us to focus on delivering the most innovative and impactful solutions on our projects and to our partners. The secure and efficient data management CDD Vault provides will enhance our ability to collaborate

with partners, further driving our success."

Evariste will now be able to securely store, organise, and share its research data with partners, streamlining the collaboration process and providing faster access to critical information. CDD Vault's advanced search and reporting tools, collaboration workflows, and customisable security settings will aid in effective data management and support the company's focus on delivering cutting-edge research and development. CDD Vault, used by top companies in pharmaceutical, biotech, and chemical industries, provides research organisations with a comprehensive solution to manage their data. Its cloud-based platform meets the needs of organisations of all sizes, making it a fitting partner for Evariste.

"We're delighted to support Evariste, a leader in the Al-drug discovery field, by providing CDD Vault. We are impressed with the velocity of their rapidly advancing R&D programs," stated Dr Barry Bunin, CEO of Collaborative Drug Discovery, Inc. "We are confident that the adoption of CDD Vault will enable them to improve their data management processes and drive innovation, as it does daily for customers around the world."

## **About Evariste**

Evariste is building the next generation of precision medicines using mathematical modelling and machine learning to identify novel targets and generate new small molecule candidates.

## About CDD Vault

CDD's (<u>www.collaborativedrug.com</u>) flagship product, "CDD Vault<sup>®</sup>", is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault<sup>®</sup> is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.

Mariana Vaschetto
Collaborative Drug Discovery
email us here

This press release can be viewed online at: https://www.einpresswire.com/article/636062565

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.